«Synendos Therapeutics»
Synendos Therapeutics
Company
Synendos Therapeutics: First-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders.
Investors
Essential Investment Partners
High-Tech Grunderfonds
Kurma Partners
Lichtsteiner Foundation
Schroder Adveq
Sunstone Life Science Ventures
Venture Kick
Ysios Capital
Zürcher Kantonal Bank
Industry:
NeuroTech
Headquarters:
Basel
Visit Website
Register and Claim Ownership
